• ImmuCell held its 2026 annual shareholder meeting on June 11, 2026.
• Shareholders elected seven director nominees to one-year terms.
• An advisory resolution on executive compensation was adopted.
• The 2025 Stock Option and Incentive Plan was approved.
• A charter amendment to add officer exculpation provisions was approved; auditor Wipfli was ratified for 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmuCell Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-020926), on June 17, 2026, and is solely responsible for the information contained therein.